In March 2025, the NPPA conducted a review of essential medicines pricing, reaffirming that allopurinol would remain exempt from price controls, thereby maintaining its market-driven pricing structure.
In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, resulting in the inclusion of allopurinol in the 24th edition, published in September 2025. This inclusion highlights the drug's continued importance in global health.
In January 2026, the FDA approved a new generic version of allopurinol, further enhancing the competitive landscape and potentially reducing costs for consumers.
In February 2026, the EMA issued updated guidelines on the manufacturing of active pharmaceutical ingredients (APIs), emphasizing stricter quality controls. This development is particularly relevant for Indian exporters, given their significant role in supplying allopurinol to the European market.
In March 2026, the CDSCO announced plans to implement more rigorous inspections of pharmaceutical manufacturing facilities, aiming to ensure compliance with international quality standards. This initiative is expected to impact allopurinol manufacturers and exporters, reinforcing the importance of maintaining high-quality production practices.
